| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/100-1/200 | Human,Mouse,Rat |
| IHC | 1/100-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human IL18 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于IL18抗体的3篇参考文献示例(注：部分文献信息为示例性概括，实际引用请核实原文准确性)：
1. **"Neutralizing IL-18 reduces inflammatory response and improves survival in a murine model of sepsis"**
- **作者**: Smith A, et al.
- **摘要**: 该研究通过中和IL18抗体在小鼠脓毒症模型中验证其疗效，发现抗体治疗显著降低促炎细胞因子水平(如TNF-α、IL-6)，并提高生存率，提示IL18可能是脓毒症治疗的潜在靶点。
2. **"IL-18 blockade ameliorates autoimmune arthritis by modulating Th1 and Th17 cell responses"**
- **作者**: Tanaka K, et al.
- **摘要**: 研究证明抗IL18抗体可通过抑制Th1/Th17细胞分化和相关炎症通路(如NF-κB)，减轻胶原诱导的关节炎模型中的关节损伤，为类风湿性关节炎治疗提供新策略。
3. **"Targeting IL-18 in cancer immunotherapy: Preclinical evidence and clinical trial updates"**
- **作者**: Zhang L, et al.
- **摘要**: 综述IL18在肿瘤微环境中的双重作用，重点讨论抗IL18抗体与免疫检查点抑制剂联用的协同效应，并汇总早期临床试验中其在黑色素瘤和结直肠癌中的安全性及疗效数据。
4. **"IL-18 binding protein fusion constructs as a novel therapeutic approach for inflammatory bowel disease"**
- **作者**: Kim H, et al.
- **摘要**: 开发了一种IL18结合蛋白-抗体融合分子，在结肠炎小鼠模型中有效中和IL18活性，减少肠道炎症和黏膜损伤，提示其作为IBD生物制剂的潜力。
(注：如需真实文献，建议通过PubMed或Web of Science以“IL-18 antibody”及具体疾病关键词检索近年高被引论文。)
Interleukin-18 (IL-18), a pro-inflammatory cytokine belonging to the interleukin-1 family, plays a pivotal role in regulating innate and adaptive immune responses. Produced primarily by macrophages, dendritic cells, and epithelial cells, IL-18 is synthesized as an inactive precursor requiring cleavage by caspase-1 (via inflammasome activation) to become biologically active. It binds to the IL-18 receptor (IL-18R), triggering downstream signaling pathways like NF-κB and MAPK, which promote the production of interferon-gamma (IFN-γ) and other inflammatory mediators. Dysregulated IL-18 signaling is implicated in autoimmune diseases (e.g., rheumatoid arthritis), chronic inflammation, and cancer.
IL-18 antibodies are tools or therapeutics designed to modulate IL-18 activity. Neutralizing monoclonal antibodies (e.g., tadekinig alfa) block IL-18 binding to its receptor, suppressing excessive inflammation in conditions like macrophage activation syndrome or adult-onset Still’s disease. Conversely, detection antibodies are used in ELISA or immunohistochemistry to quantify IL-18 levels in research or diagnostics. Challenges include IL-18's pleiotropic effects and cross-talk with cytokines like IL-12/IL-23. necessitating precise targeting. Recent studies explore combination therapies and biomarker-driven approaches to enhance therapeutic efficacy while minimizing off-target effects.
×
